BioCentury
ARTICLE | Clinical News

ABT-894: Phase II data

February 16, 2009 8:00 AM UTC

The partners discontinued the development of ABT-894 for diabetic neuropathic pain after 2 parallel, double-blind, international Phase II trials missed the primary endpoints of change in weekly averag...